Curis Reports Q3 2026 Net Loss of $8.1M with No Revenue
Curis reported a Q3 2026 net loss of $8.1 million or $1.94 per share, compared to a net loss of $7.7 million or $9.86 per share in Q3 2025; per-share loss improved year-over-year due to significantly higher share count from equity offerings. The company reported no revenue for the quarter due to the sale of Erivedge royalties to Oberland in Q4 2025, which generated $3.2 million in Q3 2025. Cash and cash equivalents totaled $5.0 million as of September 30, 2026, with the company expecting to fund operations into...
Key takeaways
Net loss improved to $1.94 per share in Q3 2026 from $9.86 per share in Q3 2025, driven by increased share count from recent equity offerings rather than improved operations
No revenue reported in Q3 2026 versus $3.2 million in Q3 2025 due to sale of Erivedge royalty rights to Oberland in Q4 2025
R&D expenses decreased to $5.6 million from $6.4 million year-over-year, primarily due to lower employee-related costs partially offset by increased clinical costs
Cash position of $5.0 million as of September 30, 2026, extended to Q1 2027 runway with $7.5 million net proceeds from October 2026 private placement
TakeAim CLL study enrolled 12 patients with initial data expected in December 2026
TakeAim Lymphoma registrational study in PCNSL showed 100% ORR in BTKi-naïve patients and 33% ORR in BTKi-experienced patients as of July 2026
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CRIS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.